2 news items
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
VKTX
4 Jun 24
, ballooning score of 0. 2) Includes all patients with baseline and post-baseline MRI, and Week 52 biopsy, with missing data imputed as non-response. 3
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
. Ligand is not responsible for, and has no role in, the development of such products or programs.
Ligand
- Prev
- 1
- Next